Downstream effectors in PTH1R signaling are also potential targets for osteoporosis.444,445 For instance, targeting the canonical Wnt/β-catenin signaling pathway and its bone-specific inhibitor sclerostin has been one of the major strategies in developing therapeutic agents for osteoporosis.446 The recently approved romosozumab was designed to target the canonical Wnt/β-catenin signaling pathway, and the drug acts as a monoclonal antibody against sclerostin.447,448. This evidence concerns the gene SOST and osteoporosis.